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Simple Summary: Cancer treatments can cause adverse effects such as cancer-related fatigue. Immune checkpoint inhibitors (ICIs) are a relatively new therapy for some cancers and have shown
great promise in helping people. Physical activity has been shown to aid many cancer patients to
overcome adverse effects in traditional chemotherapy, but along with ICIs, it hasn’t been fully examined. This study was carried out to describe where the current research is now and to find
knowledge gaps to help shape future research with ICIs, physical activity, and cancer outcomes.
Abstract: Background: Cancer therapies are associated with multiple adverse effects, including (but
not limited to) cancer-related fatigue (CRF). Fatigue is one of the most common side effects of immune checkpoint inhibitors (ICIs), occurring in up to 25% of patients. Physical activity has been
shown to help reduce CRF through modulating the immune system, and may synergistically aid in
the anti-tumor effects of ICIs. This review describes the nature and scope of evidence for the effects
associated with concurrent physical activity while undergoing ICI therapy. Method: Scoping review
methodology was utilized to identify studies, extract data, and collate and summarize results. Results: In literature published from January 2010 through to August 2021, only one human study and
three pre-clinical studies met inclusion criteria. Conclusion: Existing evidence supports that physical activity is associated with decreased treatment-related toxicities such as CRF. However, further
investigation is warranted. The dearth of clinical studies illustrates the need for more research to
address this question, to guide patients and their providers in the application of appropriate physical activity interventions in those patients undergoing ICI.
Keywords: immune checkpoint inhibitors; physical activity; exercise; exercise therapy; adverse
events; tumor growth; concurrent therapy

claims in published maps and institutional affiliations.

1. Introduction
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Immune checkpoint inhibitors (ICIs) have demonstrated clinical efficacy in multiple
cancer settings. Since the initial Food and Drug Administration (FDA) approval for an ICI
(ipilimumab) in 2011 for advanced stage melanoma, efficacy has been demonstrated in a
broad range of both solid tumors and hematologic malignancies. ICIs are now indicated
in the neoadjuvant, adjuvant, advanced/metastatic, and recurrent settings for various tumor types [1]. Additionally, pembrolizumab became the first anti-neoplastic medication
approved across solid tumors solely based on a biomarker, as a result of early studies
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including the phase 2 KEYNOTE-158 trial [2]. As the indications for ICIs expand, so too
must the medical community’s understanding of their effects, both on tumor biology and
patient-reported outcomes.
While the use of ICIs has improved outcomes in cancer, ICIs are also associated with
multiple adverse effects, such as cancer-related fatigue (CRF), which occurs in up to 25%
of patients. Physical activity has been previously shown to be effective in the milieu of
chemotherapy for decreasing the severity of chemotherapy- and cancer-related side effects [3–5]. Similarly, physical activity has been shown to reduce CRF and modulate the
immune system through multiple mechanisms in cancer patients [6,7].
Therefore, it has been postulated that physical activity may impact the outcomes of
those being treated with ICIs. Current recommendations are to be as physically active as
an individual’s abilities will allow [8]. Cancer patients are recommended to follow guidelines for healthy populations, which may not always be appropriate [9], even though
many cancer survivors have reportedly reaped great benefits from individualized fitness
regimens [10].
The utilization of ICIs has increased exponentially, and along with this use there have
been immune-related adverse events. Previous work indicates that physical activity concurrent with cancer therapy may be useful for alleviating adverse events in cancer patients; however, this is as yet unknown. The purpose of this scoping review is to describe
how physical activity is conceptualized as concurrent cancer therapy to ICIs, to identify
the evidence available in the field for the addition of physical activity to ICIs, to elucidate
the outcomes of adding physical activity to ICIs, and to identify and analyze knowledge
gaps in the field in order to further future research.
2. Materials and Methods
The scoping review was conducted according to the Joanna Briggs Institute methodology for scoping reviews, which is based predominantly on the protocols established by
Arksey and O’Malley, but also includes the revisions suggested by Levac et al. and Peters
et al. [11–15]. The review followed six steps: (1) defining the research question; (2) identifying relevant studies; (3) study selection; (4) charting the data; (5) collating, summarizing,
and reporting the results; and (6) consultation. Reporting of findings was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines using the PRISMA extension for scoping reviews (PRISMA-ScR)
checklist and is shown in Appendix A1 [16].
2.1. Inclusion and Exclusion Criteria
The scoping review was intended to include studies of individuals being treated with
ICIs for those cancers for which the FDA has approved the use of ICIs as treatment as of
31 December 2020. The focus of the review was to clarify the concept of physical activity
as concurrent therapy to ICIs, and to describe the outcomes of physical activity as concurrent therapy to ICIs in our participants of interest. Given the possibility of a scarcity of
data, the decision was made to not limit the study to human studies. For context, the review included institutional and community care settings. No restrictions were placed on
type of physical activity, so long as the activity was concurrent with administration of ICIs
and the outcomes of both physical activity and concurrent ICI administration were reported. All full-text, peer-reviewed publications published from January 2010 through to
August 2021 were included for consideration. January 2010 was chosen as a start date so
as to capture any published trial data relating to the first ICI approval in 2011.
The search was restricted to articles and reports published in English. It was restricted to full-text, peer-reviewed articles so as to be certain of the scientific rigor of the
results presented. Abstract-only publications were excluded, as were any papers that
failed to fully elucidate outcomes (editorials, etc.). Though abstracts and editorials can be
useful to help form search strategies, they can lack less-than-favorable results. By their
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abbreviated nature, abstracts do not present all data, and so were excluded. Editorials are
opinion-only.
2.2. Search Strategy
The search strategy for this review was the result of prior research in the fields of
prostate cancer and immunotherapy, as well as the strategies recommended by Tawfik et
al. for adapting searches according to database [17]. An experienced search librarian was
also consulted. The full protocol was registered at both Open Science Framework and
Figshare (https://osf.io/kb8pq/?view_only=9df23d7dd1204049a05ff37b893874c8, accessed
on 30 August 2021 and https://doi.org/10.6084/m9.figshare.16540152.v3, accessed on 30
August 2021 respectively).
The following databases were searched: PubMed, CINAHL, Cochrane Library, and
Scopus. The search terms included (but were not limited to): “neoplasms,” “cancer,” “exercise,” “activity,” “physical activit*,” and “immune checkpoint inhibitor.” Further,
MeSH terms and subject headings were also employed. A full search strategy was developed for PubMed and is shown in Appendix A2.
2.3. Data Charting Process and Extraction Items
Three members of the research team (A.L.S., S.S., and N.N.) participated in the data
extraction process. First, titles were screened for duplicates via software (EndnoteX9).
Manual screening was conducted by the same three team members. Second, titles were
screened manually for duplicates. Finally, titles and abstracts were screened based on inclusion/exclusion criteria. Screening was conducted independently, and the inclusion
forms were compared for consistency. Upon agreement, full-text review was then conducted independently. From each article, the following information was charted: author,
year of publication, title, ICI, country of origin, study type, study population, operationalization of exercise/physical activity, primary objective(s), and outcome(s)/summary.
Blank inclusion and extraction forms are included in the supplemental materials.
2.4. Synthesis of Results
In the event that studies utilized similar physical activity and ICIs, a systematic review and meta-analysis would be the ideal synthesis tool. However, a narrative synthesis
was instead chosen, given the broad scope of the question, the desire of the research team
to allow for multiple forms of physical activity, and the relatively new nature of the field.
The articles were grouped according to subject type (pre-clinical, clinical). As there was
only 1 human study which included prospectively collected data and 3 murine randomized control trials, a critical appraisal of evidence within trials was deemed unnecessary
for this review.
3. Results
3.1. Selection of Sources of Evidence
The literature search retrieved 800 articles. Computer software eliminated 45 duplicates. An additional 15 duplicates were manually eliminated. The remaining 740 abstracts
were screened and, with the addition of 2 articles found through other sources, 24 articles
were identified for full-text review. After the full-text review, 4 articles remained for inclusion in the scoping review, having fulfilled all inclusion criteria. The most frequently
cited reasons for article exclusion were lack of an ICI and lack of a concurrent physical
activity intervention during ICI therapy (Figure 1).
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Figure 1. PRISMA Flow Chart of Studies included in the review.

3.2. Characteristics of Sources of Evidence
The studies’ characteristics are summarized in Table 1. The studies ranged in time of
publication from 2018 to 2021. Three of the studies were pre-clinical randomized control
trials [18–20] and one was a prospective clinical cohort pilot study [21]. The most common
form of physical activity was running a treadmill [19,20], and PD-1/PD-L1 inhibitors were
used in all studies. Two of the studies examined the response in melanoma tumors [18,21],
one considered breast tumor response [19], and one utilized non-small cell lung cancer
(NSCLC) [20].
Table 1. Selected study characteristics.

Authors

1

Lacey, J. et
al. (2018)
[21]

Study Design

Population
ICI
Characteristics
Clinical/Human

N = 28 MM patients; 13 intervention, 15 control; (3
Pre-/Post-test non-complete); age
cohort design 42–85, median 66;
16 male, 12 female;
median 2.75 years
since diagnosis

Pembrolizumab

Pre-Clinical/Murine

Physical
Activity

Outcome

1 hr consultation w/exercise
physiologist to design an
exercise program that included 16 sessions of physical activity tailored to paAdherence, patient’s preferences and catient-reported
pabilities and an activity symptoms, anxiety
monitor; review throughout and depression,
9-week trial and follow-up
and toxicity
at completion of 9 weeks;
included aerobic, resistance,
and other (qi gong, yoga,
etc.)
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2

Bay, M.L. et
al. (2020)
[18]

RCT

3

Gomes-Santos, I.L. et al.
(2021) [19]

RCT

4

MartínRuiz, A. et
al. (2020)
[20]

RCT

5 of 16

8–16 weeks old
C57BL/6 mice with
subcutaneous tuPD-L1 and
mors
PD-1 inhibitor
Immune response
(B16 melanoma tutreatment
in an immunologimors); all female; 4
After tumor Voluntary wheel running cally ‘cold’ tumor;
groups N = 14 (coninoculation, Mice had access to wheels Tumor growth,
trol sedentary, coninjections
for 5 weeks prior to study changes in body
trol exercising,
were 3x per
weight and spleen
treated sedentary,
week for 2
weight
and treated exercisweeks
ing); identical studies of PD-L1 and
PD-1 inhibitors
Immune
8–10 weeks old fe- checkpoint
Treadmill to mimic modermale C57BL/6, FVB, blockade
ate-to-vigorous intensity
Balb/c mice; breast (ICB): antiTime for tumor
prescribed by American
tumor tissue at
PD-1 alone,
growth; tumor and
College of Sports Medicine
100mm3 signaled
anti-PD-1
surrounding vas30–60 min. 3–5 d/wk; exerstudy start; CD8+T with anticulature; immune
cise training of 45 min/d
cells depleted prior CTLA-4 or
cell counts
treadmill time at 60% maxito study start; n = 6 IgG adminismal velocity
mice per group tered concurrent with ExTr
Human NSCLC tissue (previously untreated basaloid infiltrating squamous
cell stage IIA) and
Aerobic and resistance
patient derived
training 5 days per week; Aerobic capacity,
xenograft (PDX)
aerobic 5 days/week: tread- forelimb grip
mice; 8-week-old
mill work up to 80% max strength, tumor
female mice; 100 Nivolumab
velocity, strength 2 days
volume and
mm3 tumor size inper week: horizontal screen growth rate, cell
cluded; non-exerexercise (climbing), hangproliferation,
cise control n = 5,
ing with two limbs; 8-week
apoptosis,
exercise control n =
intervention
5, exercise +
nivolumab n = 6,
non-exercise +
nivolumab n = 6

3.3. Key Findings
The main outcomes measured in the clinical study were feasibility, patient-reported
symptoms, anxiety and depression, toxicity, and patient adherence [21]. Multiple myeloma patients treated with pembrolizumab were recruited to test the feasibility of a multimodal support program. The program included care provided by physicians, dieticians,
and exercise physiologists. The patients had low numbers of adverse events both pre- and
post-study, the most prevalent being fatigue and sleep issues. The physical activity intervention was shown to be feasible with an 85% completion rate. Limitations of this study
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included the small sample size, the mixing of cohorts in which patients were both initiating and pre-established on treatment with ICIs, and the self-selective nature of the control
group.
The main focuses of the pre-clinical studies were tumor size and growth rate [18–20].
All three murine studies indicated that physical activity slowed tumor growth, slowed
immune cell proliferation, and improved immune sensitivity [18–20].
Bay et al. tested the addition of physical activity via voluntary wheel running to immune checkpoint blockade (either PD-1 or PD-L1) on tumor growth and gene expression
of immune regulatory molecules [18]. Wheel running alone was found to increase expression of PD-1, PD-L1 and PD-L2 significantly. In this same model, tumor growth was reduced by 72% in mice who demonstrated voluntary physical activity when compared to
the inactive control mice (p = 0.13). Mice who participated in voluntary physical activity
and were treated with a PD-L1 inhibitor showed an 83% reduction in the rate of tumor
growth (p < 0.05) compared to the rate of growth in the sedentary group. A 50% rate of
tumor growth reduction was seen in mice with physical activity combined with PD-1
blockade (p = 0.07) compared to sedentary mice. The researchers found no additional advantage to administering both PD-1 and PD-L1 blockade along with physical activity.
Gomes-Santos et al. studied the effect of physical activity, concurrent with anti-PD-1
alone or in combination with anti-CTLA-4 treatment, on tumor growth and the tumor
environment [19]. The study used mice to model human breast cancer and treadmills for
physical activity. Physical activity was able to decrease the rate of tumor growth, as well
as induce vessel normalization. Seven days of exercise training in three different models
of breast cancer resulted in reduced tumor burden (approximately 30% decrease in tumor
weight; model 1: ~600 mg vs 400 mg; model 2: ~600 mg vs 450 mg; model 3: ~825 mg vs
600 mg). The tumor microenvironment of treadmill mice had increased perfusion and decreased hypoxia. There was no change in blood vessel density, but a positive impact was
reported on the fraction of blood vessels that were perfused. RNA sequencing also confirmed that there was reprogramming of the tumor microenvironment towards more oxidative phosphorylation and less immunosuppression. These changes had important implications on the sensitivity of the breast cancer model; mice treated with a combination
of immunotherapies directed at both PD-1 and CTLA-4 as well as scripted exercise had
delayed tumor growth and decreased tumor volume compared to sedentary mice. Finally,
physical activity prevented CRF in immune-checkpoint-blockade-treated mice, as measured by preservation of exercise capacity, demonstrated through increased time to exhaustion (~1500 sec vs ~2500 sec; p < 0.001) and total running distance ~450 m vs ~1000 m;
p < 0.001) compared to the control group.
Martín-Ruiz utilized a murine model of non-small cell lung cancer (NSCLC) to study
the effects of physical activity in combination with nivolumab therapy [20]. The animals
in this study experienced both treadmill running to target aerobic capacity, as well as cage
climbing and bar hanging for strength training. Similar to the Bay et al. study, physical
activity alone reduced tumor growth rate in comparison to sedentary mice (p = 0.05).
When nivolumab was added to the regimen, tumor death (p = 0.026) and apoptosis (p =
0.030) were increased among the physically active mice. As expected, aerobic capacity and
strength improved in the active mice. Of note, neutrophil tumor infiltration was higher in
the physically active group in combination with nivolumab group (p = 0.018) compared
to the inactive group, and VEGF-A expression was higher in the nivolumab group, regardless of physical activity status.
4. Discussion
The aim of this scoping review was to elucidate the extent of published research evaluating the effects of concurrent physical activity interventions and the use of ICIs. To the
authors’ knowledge, this is the first scoping review to focus on studies that assess the
concurrent administration of ICIs and a physical activity regimen. Our results identify a
major gap in human-based research in the field. Part of the reason for this may be the
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relatively new nature of the medications that are still undergoing trials for approvals in
different cancer types. Another reason may be a lack of trained practitioners to aid patients
as described by Santa Mina et al. [22] This may have led to human studies being proposed
but not reaching completion, and therefore remaining unpublished. Many of the studies
published to date have been during the survivorship phase rather than during active treatment, which limits the availability of data on the direct synergistic effect of physical activity on cancer therapy.
As a concept, physical activity is considered to be complementary to immune checkpoint blockade. From pre-clinical to clinical studies, “physical activity” was viewed as
anything from wheel-running, to strength training, to walking, to qi-gong and yoga. The
pre-clinical studies indicate that the combination of physical activity and checkpoint inhibition is advantageous to the patient through decreased tumor growth, improved
strength, decreased fatigue, and improved ability of the immune system to fight cancer.
4.1. Physiology of Exercise and Immunology
There is a growing body of evidence investigating the mechanisms by which exercise
modulates immunity. Much of this research points to effects on natural killer (NK) and T
cells, rather than to components of humoral immune responses [7]. These are also the immune cells that are targeted by ICIs, indicating that the anti-tumor effects of both exercise
and checkpoint blockade may be synergistic.
It has been shown that sedentary patients have higher proportions of both CD4+ and
CD8+ T cells that express PD-1, a negative immunologic regulator [23]. Meanwhile, CD8+
cytotoxic T cells are mobilized by acute exercise, and thus more able to participate in active
immunity [24]. Exercise further induces the proliferation and activation of T cells against
tumors, likely through adrenergic stimulation [25]. Finally, T cells that undergo repeated
stimulation suffer from both senescence (a decreased ability to replicate partially due to
telomere shortening) and exhaustion (the loss of vital functions). However, these two processes of immune impairment are attenuated by the effects of exercise [26].
As the blockade of PD-L1, PD-1, and CTLA-4 by ICIs results in the activation of T
cells, it stands to reason that this effect would be augmented by exercise through the above
mechanisms. In fact, this was demonstrated in a mouse model of breast cancer, which
showed that exercise slowed immunosuppressive elements of the tumor microenvironment and induced increases in CD8+ T cell activation [27]. This was tested in the presence
of radiotherapy (RT) plus PD-1 blockade. The investigators found that the addition of exercise to RT+PD-1 blockade increased splenic CD8+ T cells, decreased PD-1 expression on
NK cells, increased markers of NK-cell activation, and ultimately slowed tumor growth.
Although there are clearly physiologic reasons for synergism with immunotherapies,
physical activity has also been shown to improve outcomes when combined with chemotherapy. One study in breast cancer patients found that a physical activity regimen was
adhered to more closely while patients were undergoing therapy, as compared with when
after therapy was complete; and higher adherence occurred during chemotherapy than
during radiotherapy [28]. In lung cancer, across the cancer continuum, increased physical
activity was found to be safe and sought-after by patients, and shown to improve quality
of life [29].
Similarly, a recent study indicated that the combination of diet, physical activity, and
chemotherapy improved the efficacy of chemotherapy in patients with acute lymphoblastic leukemia [30]. Compared to usual care, those patients who participated with a diet
and physical activity program during treatment saw a reduction in minimal residual disease.
Similarly to the murine results of the Martín-Ruiz et al. study, Reis et al. found an
increase in in both functional and aerobic capacity in human breast cancer patients undergoing treatment [20,31]. Reis et al. also found a decrease in pain scores and an increase in
strength for those undergoing a physical activity regimen during their chemotherapy.
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There was no significant finding for fatigue. Likewise, the OptiTrain group found lower
rates of thrombocytopenia in their exercising group compared to usual care [32].
4.2. Strengths and Limitations
This scoping review had a number of strengths. The review used a strong and transparent methodology. A protocol was followed and was registered before research began.
A broad search of the literature was conducted in four databases. Finally, the review was
conducted by a multidisciplinary team. The review also had some limitations. To manage
scope, we excluded studies without clearly defined outcomes, as well as abstracts. However, the abstracts that were eliminated on full scan could have also been eliminated for
lack of concurrent therapy. Another limitation is the use of articles published only in English in the review. Articles examining the topic in other languages may have been missed
in the search. The study included only four articles, and so the synthesis of results is limited.
5. Conclusions
The results of the scoping review suggest that the current availability of research is
lacking to inform the use of concurrent administration of physical activity or increased
physical activity and ICIs. Pre-clinical studies suggest that the addition of physical activity, whether as a prescribed regimen or as a voluntary practice, has benefits both in tumor
growth rate and volume. Those studies also show an improvement in strength and in immune response. The clinical pilot study showed efficacy for the addition of physical activity to immunotherapy. Prior studies indicate that the addition of physical activity benefits
chemotherapy. There is a need now to perform more clinical studies combining physical
activity with immunotherapy, so as to inform clinicians and improve outcomes for patients.
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Appendix A1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Extension for Scoping Reviews (PRISMA-ScR) Checklist
Table A1. PRISMA-ScR Checklist.

Section

Item

Title

1

Structured
summary

2

Rationale

3

Objectives

4

Protocol and
registration

5

Eligibility criteria

6

Information sources

7

PRISMA-ScR Checklist Item
Title
Identify the report as a scoping
review.
Abstract
Provide a structured summary
that includes (as applicable):
background, objectives, eligibility criteria, sources of evidence,
charting methods, results, and
conclusions that relate to the review questions and objectives.
Introduction
Describe the rationale for the review in the context of what is already known. Explain why the
review questions/objectives lend
themselves to a scoping review
approach.
Provide an explicit statement of
the questions and objectives being addressed with reference to
their key elements (e.g., population or participants, concepts,
and context) or other relevant
key elements used to conceptualize the review questions
and/or objectives.
Methods
Indicate whether a review protocol exists; state if and where it
can be accessed (e.g., a Web address); and if available, provide
registration information, including the registration number.
Specify characteristics of the
sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.
Describe all information sources
in the search (e.g., databases
with dates of coverage and contact with authors to identify additional sources), as well as the

Reported on Page
1

1

2

2

2-3

2

2
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Search

8

Selection of sources of evidence

9

Data charting
process

10

Data items

11

Critical appraisal of individual sources of evidence

12

Synthesis of results

13

Selection of sources of evidence

14

Characteristics of sources of
evidence

15

Critical appraisal within
sources
of evidence

16

date the most recent search was
executed.
Present the full electronic search
strategy for at least 1 database,
including any limits used, such
that it could be repeated.
State the process for selecting
sources of evidence (i.e., screening and eligibility) included in
the scoping review.
Describe the methods of charting data from the included
sources of evidence (e.g., calibrated forms or forms that have
been tested by the team before
their use, and whether data
charting was performed independently or in duplicate) and
any processes for obtaining and
confirming data from investigators.
List and define all variables for
which data were sought and
any assumptions and simplifications made.
If carried out, provide a rationale for conducting a critical
appraisal of included sources of
evidence; describe the methods
used and how this information
was used in any data synthesis
(if appropriate).
Describe the methods of handling and summarizing the data
that were charted.
Results
Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using
a flow diagram.
For each source of evidence,
present characteristics for which
data were charted and provide
the citations.
If carried out, present data on
critical appraisal of included
sources of evidence (see item
12).

Appendix Table A2

2

3

3

3

3

4

4-6

3
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Results of
individual sources of evidence

17

Synthesis of results

18

Summary of
evidence

19

Limitations

20

Conclusions

21

Funding

22

For each included source of evidence, present the relevant data
that were charted that relate to
the review questions and objectives.
Summarize and/or present the
charting results as they relate to
the review questions and objectives.
Discussion
Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives,
and consider the relevance to
key groups.
Discuss the limitations of the
scoping review process.
Provide a general interpretation
of the results with respect to the
review questions and objectives,
as well as potential implications
and/or next steps.
Funding
Describe sources of funding for
the included sources of evidence, as well as sources of
funding for the scoping review.
Describe the role of the funders
of the scoping review.

4-6

4, 6

7

8

8

9
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Appendix A2
Table A2. PubMed Search.
Database

PubMed

Search Terms
(“bladder cancer”[All Fields] OR “bc”[All Fields] OR “cancer*”[All Fields] OR “cc”[All Fields] OR “cervical cancer”[All Fields] OR “cHL”[All Fields] OR “classical Hodgkin’s lymphoma”[All Fields] OR “Colorectal Neoplasms”[MeSH Terms] OR “metastatic colorectal cancer”[All Fields] OR “colorectal cancer”[All Fields] OR
“CRC”[All Fields] OR “CSCC”[All Fields] OR “cutaneous
squamous cell carcinoma”[All Fields] OR “endometrial
cancer”[All Fields] OR “ec”[All Fields] OR “Endometrial
Neoplasms”[MeSH Terms] OR “esophageal squamous cell
carcinoma”[All Fields] OR “ESCC”[All Fields] OR “gastric
carcinoma”[All Fields] OR “gc”[All Fields] OR “gastroesophageal junction carcinoma”[All Fields] OR “GEJ
carcinoma”[All Fields] OR “head and neck cancer”[All
Fields] OR “HNC”[All Fields] OR “HNSC”[All Fields] OR
“Head and Neck Neoplasms”[MeSH Terms] OR “hepatocellular carcinoma”[All Fields] OR “HCC”[All Fields] OR
“locally advanced”[All Fields] OR “lymphoma*”[All
Fields] OR “Lymphoma”[MeSH Terms] OR “Melanoma”[MeSH Terms] OR “MCC”[All Fields] OR “Merkel
cell carcinoma”[All Fields] OR “metastatic Merkel Cell
carcinoma”[All Fields] OR “metastatic melanoma”[All
Fields] OR “metastatic squamous NSCLC”[All Fields] OR
“metastatic NSCLC”[All Fields] OR “metastatic non-squamous NSCLC”[All Fields] OR “non-squamous
NSCLC”[All Fields] OR “carcinoma, non-small cell
lung”[MeSH Terms] OR “carcinoma”[All Fields] OR “nonsmall cell”[All Fields] OR “lung”[All Fields] OR “nonsmall-cell lung carcinoma”[All Fields] OR “nsclc”[All
Fields] OR “non-small cell lung cancer”[All Fields] OR
“unresectable stage III NSCLC”[All Fields] OR “Neoplasms”[MeSH Terms] OR “neoplasia*”[All Fields] OR
“pm”[All Fields] OR “pleural mesothelioma”[All Fields]
OR “PMBCL”[All Fields] OR “primary mediastinal large B
cell lymphoma”[All Fields] OR “advanced RCC”[All
Fields] OR “RCC”[All Fields] OR “renal cell carcinoma”[All Fields] OR “small cell lung cancer”[All Fields]
OR “SCLC”[All Fields] OR “solid tumor”[All Fields] OR
“squamous cell head and neck cancer”[All Fields] OR “triple-negative breast cancer”[All Fields] OR “TNBC”[All
Fields] OR “unresectability”[All Fields] OR “unresectable”[All Fields] OR “unresected”[All Fields] OR “urinary bladder neoplasms”[All Fields] OR “urothelial carcinoma”[All Fields] OR “metastatic urothelial carcinoma”[All Fields])

Results

360
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AND
(“exercise*”[All Fields] OR “Exercise”[MeSH Terms] OR
“Exercise Therapy”[All Fields] OR “Exercise Therapy”[MeSH Terms] OR (“physical examination”[MeSH
Terms] OR “physical examination”[All Fields] OR “physical”[All Fields] OR “physically”[All Fields] OR “physicals”[All Fields] OR “physical activit*”[All Fields] OR
“weight-bearing exercise”[All Fields] OR “weight-bearing”[All Fields] OR “weight-bearing training”[All Fields]
OR “strength training”[All Fields] OR “training”[All
Fields] OR “aerobic”[All Fields] OR “aerobically”[All
Fields] OR “Exercise”[All Fields] OR “aerobics”[All
Fields] OR “aerobic training”[All Fields] OR “aerobic exercise”[All Fields] OR “aerobic activit*”[All Fields] OR “rehabilitant”[All Fields] OR “rehabilitants”[All Fields] OR
“rehabilitate”[All Fields] OR “rehabilitated”[All Fields]
OR “rehabilitates”[All Fields] OR “rehabilitating”[All
Fields] OR “Rehabilitation”[MeSH Terms] OR “Rehabilitation”[All Fields] OR “rehabilitations”[All Fields] OR “rehabilitative”[All Fields] OR “Rehabilitation”[MeSH Subheading] OR “rehabilitations”[All Fields] OR “rehabilitational”[All Fields] OR “rehabilitator”[All Fields] OR “rehabilitators”[All Fields] OR “physical rehabilitation”[All
Fields] OR “HIIT”[All Fields] OR “high intensity interval
training”[All Fields] OR “therapeutic exercise”[All Fields]
OR “aerobic conditioning”[All Fields] OR “rehabilitative
exercise”[All Fields] OR “physical therapy modalities”[MeSH Terms] OR (“physical”[All Fields] AND “therapy”[All Fields] AND “modalities”[All Fields]) OR “physical therapy modalities”[All Fields] OR “physiotherapies”[All Fields] OR “physiotherapy”[All Fields] OR “resistance training”[All Fields] OR “Exercise Movement
Techniques”[MeSH Terms]))
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AND
(“immunomodulatory”[All Fields] OR “immune therapy”[All Fields] OR “immune checkpoint inhibitors”[All
Fields] OR “ICI”[All Fields] OR “anti-PD-1 monoclonal
antibody”[All Fields] OR “pembrolizumab”[Supplementary Concept] OR “pembrolizumab”[All Fields] OR “pembrolizumab”[Supplementary Concept] OR “pembrolizumab”[All Fields] OR “keytruda”[All Fields] OR “antiCTLA-4 monoclonal antibody”[All Fields] OR
“tremelimumab”[Supplementary Concept] OR
“tremelimumab”[All Fields] OR “nivolimumab”[All
Fields] OR “nivolumab”[MeSH Terms] OR
“nivolumab”[All Fields] OR “opdivo”[All Fields] OR
“ipilimumab”[MeSH Terms] OR “ipilimumab”[All Fields]
OR “ipilimumab”[MeSH Terms] OR “ipilimumab”[All
Fields] OR “yervoy”[All Fields] OR “avelumab”[Supplementary Concept] OR “avelumab”[All Fields] OR
“avelumab”[Supplementary Concept] OR “avelumab”[All
Fields] OR “bavencio”[All Fields] OR “durvalumab”[Supplementary Concept] OR “durvalumab”[All Fields] OR
“cemiplimab”[Supplementary Concept] OR “cemiplimab”[All Fields] OR “durvalumab”[Supplementary
Concept] OR “durvalumab”[All Fields] OR “imfinzi”[All
Fields] OR “cemiplimab”[Supplementary Concept] OR
“cemiplimab”[All Fields] OR “libtayo”[All Fields] OR
“atezolizumab”[Supplementary Concept] OR “atezolizumab”[All Fields] OR “tecentriq”[All Fields] OR
“PD1”[All Fields] OR “PDL1”[All Fields] OR
“CTLA4”[All Fields] OR “PD-1”[All Fields] OR “PDL1”[All Fields] OR “ctla 4 antigen”[MeSH Terms] OR “ctla
4 antigen”[All Fields] OR “ctla 4”[All Fields])
AND
(2010/01/01:2021/08/31[Date-Publication] AND “english”[Language]))) AND ((fft[Filter]) AND
(2010/1/1:2021/8/31[pdat]) AND (english[Filter]) AND (alladult[Filter]))
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